- Both obesity and cardiovascular disease can increase a person’s risk of developing kidney disease.
- A recent study found that semaglutide may help reduce the progression of kidney disease in people with type 2 diabetes.
- A new study from researchers at the University of Edinburgh, in the United Kingdom, says semaglutide may also help protect kidney function in people who are overweight or obese with established cardiovascular disease.
Previous research shows that both
A recently published study found that
Now, research recently presented at the 61st European Renal Association Conference in Stockholm, Sweden, reports semaglutide may also help protect kidney function in people who have overweight or obesity and also have established cardiovascular disease.
The research has not yet been published in a peer-reviewed journal.
This study’s results are from the
After an average follow-up of about 3.5 years, scientists discovered that adverse kidney-related events — such as a significant decline in kidney function, death from kidney causes, or onset of persistent macroalbuminuria — were experienced by 22% fewer participants in the group receiving semaglutide injections compared to the placebo group.
“By addressing key markers of kidney health, semaglutide 2.4 mg [milligrams] weekly may contribute to a significant reduction in the risk of kidney-related complications, including chronic kidney disease and end-stage renal disease,” said Prof. Helen M. Colhoun, MD, the AXA Chair in Medical Informatics and Life Course Epidemiology…
Read the full article here